314 related articles for article (PubMed ID: 23592524)
21. [A case of rectal carcinoid with multiple liver, lymph nodes and bone metastases that responded to an octreotide therapy].
Yamashita K; Takase S; Nakamura T; Matsuda Y; Imanishi T; Sumi Y; Suzuki S; Kamigaki T; Ku Y; Kuroda D
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2349-51. PubMed ID: 21224569
[TBL] [Abstract][Full Text] [Related]
22. Carcinoid crisis 24 hours after bland embolization: A case report.
Fujie S; Zhou W; Fann P; Yen Y
Biosci Trends; 2010 Jun; 4(3):143-4. PubMed ID: 20592464
[TBL] [Abstract][Full Text] [Related]
23. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
Kölby L; Persson G; Franzén S; Ahrén B
Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
[TBL] [Abstract][Full Text] [Related]
24. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
25. The prophylactic use of octreotide in a patient with ovarian carcinoid and valvular heart disease.
Watson JT; Badner NH; Ali MJ
Can J Anaesth; 1990 Oct; 37(7):798-800. PubMed ID: 2225298
[TBL] [Abstract][Full Text] [Related]
26. Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome.
Zomerhuis MT; Hussain SM; Feelders RA; van der Lely AJ; de Herder WW
Neuroendocrinology; 2005; 82(1):41-8. PubMed ID: 16391492
[TBL] [Abstract][Full Text] [Related]
27. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
Shen C; Shih YC; Xu Y; Yao JC
Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
[TBL] [Abstract][Full Text] [Related]
28. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
Shen C; Shih YC; Xu Y; Yao JC
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
[TBL] [Abstract][Full Text] [Related]
29. Anesthetic considerations and management of a patient with unsuspected carcinoid crisis during hepatic tumor resection.
Choi CK
Middle East J Anaesthesiol; 2014 Jun; 22(5):515-8. PubMed ID: 25137869
[TBL] [Abstract][Full Text] [Related]
30. Treatment of liver metastases of carcinoid tumors.
Ahlman H; Westberg G; Wängberg B; Nilsson O; Tylén U; Scherstén T; Tisell LE
World J Surg; 1996 Feb; 20(2):196-202. PubMed ID: 8661817
[TBL] [Abstract][Full Text] [Related]
31. Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.
Seymour N; Sawh SC
Can J Anaesth; 2013 May; 60(5):492-9. PubMed ID: 23328959
[TBL] [Abstract][Full Text] [Related]
32. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
[TBL] [Abstract][Full Text] [Related]
33. [Clinical images in gastrology. Carcinoid tumor metastatic liver].
Cortés-Espinosa T; de la Cruz-Guillén A; Manzano-Cortés H
Rev Gastroenterol Mex; 2008; 73(4):247. PubMed ID: 19666276
[No Abstract] [Full Text] [Related]
34. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
[TBL] [Abstract][Full Text] [Related]
35. Update on carcinoid syndrome.
Melnyk DL
AANA J; 1997 Jun; 65(3):265-70. PubMed ID: 9233098
[TBL] [Abstract][Full Text] [Related]
36. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
37. Palliative management strategies of advanced gastrointestinal carcinoid neoplasms.
Sartori P; Mussi C; Angelini C; Crippa S; Caprotti R; Uggeri F
Langenbecks Arch Surg; 2005 Sep; 390(5):391-6. PubMed ID: 15968542
[TBL] [Abstract][Full Text] [Related]
38. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
[TBL] [Abstract][Full Text] [Related]
39. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
40. [Analogs of somatostatin and carcinoid tumors].
Gutiérrez Rodero F; Morales Cano JM; de Blas Laborda C; González Barber A
Med Clin (Barc); 1990 Jun; 95(2):78-9. PubMed ID: 2250512
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
